TOWA Pharmaceutical - Public Comps and Valuation Multiples

TOWA Pharmaceutical Overview

About TOWA Pharmaceutical

TOWA Pharmaceutical Co Ltd is a Japan based pharmaceutical company engaged in research and development, production, and marketing of generic drugs. It also provides drug consulting services for patients and their families and relatives. It organizes academic seminars for medical professionals and posts articles in journals. It participates in training for pharmacists. The company has three main plants in operation namely Osaka plant, Okayama plant, and Yamagata plant. Towa has offers more than 500 drugs to meet the diverse therapeutic requirements including lifestyle related diseases such as hypertension and diabetes, digestive system diseases, nervous system diseases and allergic diseases, vitamins and antibiotics.

Founded

1957

HQ

Employees

3.1K+

Website

towayakuhin.co.jp

Sectors

Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $1.8B

LTM EBITDA $297M

EV

$2.1B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

TOWA Pharmaceutical Financials

As of September 2025, TOWA Pharmaceutical reported last 12-month revenue of $1.8B and EBITDA of $297M.

In the same period, TOWA Pharmaceutical generated $653M in LTM gross profit and $116M in net income.

See TOWA Pharmaceutical valuation multiples based on analyst estimates

TOWA Pharmaceutical P&L

In the most recent fiscal year, TOWA Pharmaceutical reported revenue of $1.7B and EBITDA of $315M.

TOWA Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX

See TOWA Pharmaceutical valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$1.8B	XXX	$1.7B	XXX	XXX	XXX
Gross Profit	$653M	XXX	$621M	XXX	XXX	XXX
Gross Margin	37%	XXX	36%	XXX	XXX	XXX
EBITDA	$297M	XXX	$315M	XXX	XXX	XXX
EBITDA Margin	17%	XXX	19%	XXX	XXX	XXX
EBIT	$162M	XXX	$152M	XXX	XXX	XXX
EBIT Margin	9%	XXX	9%	XXX	XXX	XXX
Net Profit	$116M	XXX	$125M	XXX	XXX	XXX
Net Margin	7%	XXX	7%	XXX	XXX	XXX
Net Debt	XXX	XXX	$1.1B	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for TOWA Pharmaceutical including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $1.8B. EBITDA for the last twelve months was $297M. In the most recent fiscal year, TOWA Pharmaceutical achieved $1.7B in revenue and $315M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$1.8B	Analyst estimates available to subscribers	$1.7B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$653M	Analyst estimates available to subscribers	$621M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	36.8% gross margin	Analyst estimates available to subscribers	36.5% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$297M	Analyst estimates available to subscribers	$315M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	16.8% EBITDA margin	Analyst estimates available to subscribers	18.5% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$162M	Analyst estimates available to subscribers	$152M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	9.1% EBIT margin	Analyst estimates available to subscribers	9.0% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$116M	Analyst estimates available to subscribers	$125M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	6.5% net profit margin	Analyst estimates available to subscribers	7.3% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$1.1B	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for TOWA Pharmaceutical

This financial data table provides comprehensive performance metrics for TOWA Pharmaceutical, a company based in Japan. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

TOWA Pharmaceutical generated $1.8B in revenue over the last twelve months.
The company achieved $297M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $653M.
Net income over the last twelve months reached $116M.

Fiscal Year Performance

In the most recent fiscal year, TOWA Pharmaceutical reported $1.7B in total revenue.
Fiscal year EBITDA was $315M.
The company maintained a gross profit margin of 36.5% in the most recent fiscal year.
EBITDA margin for the fiscal year was 18.5%.
Net profit margin reached 7.3% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for TOWA Pharmaceutical. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

TOWA Pharmaceutical Stock Performance

TOWA Pharmaceutical has current market cap of JPY 140B (or $918M), and EV of JPY 325B (or $2.1B).

Market Cap Evolution

TOWA Pharmaceutical Stock Data

As of October 17, 2025, TOWA Pharmaceutical's stock price is JPY 2843 (or $19).

See TOWA Pharmaceutical trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$2.1B	$918M	XXX	XXX	XXX	XXX	$2.35

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

TOWA Pharmaceutical Valuation Multiples

TOWA Pharmaceutical's trades at 1.3x EV/Revenue multiple, and 6.9x EV/EBITDA.

See valuation multiples for TOWA Pharmaceutical and 15K+ public comps

TOWA Pharmaceutical Financial Valuation Multiples

As of October 17, 2025, TOWA Pharmaceutical has market cap of $918M and EV of $2.1B.

Equity research analysts estimate TOWA Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

TOWA Pharmaceutical has a P/E ratio of 7.9x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$918M	XXX	$918M	XXX	XXX	XXX
EV (current)	$2.1B	XXX	$2.1B	XXX	XXX	XXX
EV/Revenue	1.2x	XXX	1.3x	XXX	XXX	XXX
EV/EBITDA	7.2x	XXX	6.9x	XXX	XXX	XXX
EV/EBIT	13.2x	XXX	14.9x	XXX	XXX	XXX
EV/Gross Profit	3.3x	XXX	n/a	XXX	XXX	XXX
P/E	7.9x	XXX	7.7x	XXX	XXX	XXX
EV/FCF	-66.8x	XXX	-23.8x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get TOWA Pharmaceutical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

TOWA Pharmaceutical Margins & Growth Rates

TOWA Pharmaceutical's last 12 month revenue growth is 6%

TOWA Pharmaceutical's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.

TOWA Pharmaceutical's rule of 40 is 25% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

TOWA Pharmaceutical's rule of X is 33% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for TOWA Pharmaceutical and other 15K+ public comps

TOWA Pharmaceutical Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	6%	XXX	7%	XXX	XXX	XXX
EBITDA Margin	17%	XXX	19%	XXX	XXX	XXX
EBITDA Growth	9%	XXX	3%	XXX	XXX	XXX
Rule of 40	25%	XXX	25%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	33%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.5M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	28%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial